In 2021, the team conducted further research and discovered that the synergistic effect of IP and tight-junction-opening peptide AT1002 analogs can overcome psoriasis skin thickening and enable the intradermal delivery of NF-κB-inducible oligodeoxynucleotides for psoriasis treatment [118]. Here, NFKB1 is linked to psoriasis.